The disclosure relates to a pharmaceutical composition for preventing or treating hyperlipidemia comprising (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({ 2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl} methyl)-4-methyl-1,3-oxazolidin-2-one represented by the structural formula shown herein or its pharmaceutically acceptable salt； and an angiotensin II receptor blocker as active ingredients, wherein the angiotensin II receptor blocker is selected from the group consisting of olmesartan or its salt, olmesartan medoxomil or its salt, telmisartan or its salt, losartan or its salt, and valsartan or its salt, wherein the hyperlipidemia is hypercholesterolemia, hypertriglyceridemia or hypertriglyceridemia-associated disease such as atherosclerosis or pancreatitis.
